Table 4. Association between serum 25-hydroxyvitamin D and C-reactive protein in subjects with data on osteoporosis available.
| N | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|
| Beta (95% CI) | Beta (95% CI) | Beta (95% CI) | ||
| <50 nmol/l | 1,579 | Reference | Reference | Reference |
| 50–75 nmol/l | 749 | -0.22 (-0.31, -0.12) | -0.12 (-0.21, -0.03) | -0.12 (-0.21, -0.03) |
| >75 nmol/l | 418 | -0.26 (-0.37, -0.14) | -0.15 (-0.26, -0.04) | -0.15 (-0.26, -0.04) |
| P for trend | 6.15×10−7 | 0.003 | 0.003 | |
| Per SD 25OHD* | 2,746 | -0.12 (-0.17, -0.08) | -0.07 (-0.12, -0.03) | -0.07 (-0.11, -0.02) |
| P-value | 5.48×10−7 | 0.004 | 0.004 |
Model 1: adjusted for age and sex
Model 2: adjusted for age, sex, body mass index, total cholesterol to high-density lipoprotein ratio, systolic blood pressure, prevalent diabetes mellitus, estimated glomerular filtration rate, smoking, alcohol intake, season and level of education
Model 3: additionally adjusted for osteoporosis
* 25OHD denotes 25-hydroxyvitamin D.